Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
The move comes after a death in the Alpha-3 cema-cel study.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
The first data are dribbled out, but cross-trial comparisons look uninspiring.
